{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:06:28Z","timestamp":1781103988720,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Foundation from Shanghai Municipal Science and Technology Commission","award":["23ZR1410700; 23Y11902100"],"award-info":[{"award-number":["23ZR1410700; 23Y11902100"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2023J011692"],"award-info":[{"award-number":["2023J011692"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14331-5","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T19:35:17Z","timestamp":1748806517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synergistic effects of PD-1 antibody and chemotherapy followed by surgery-centric local treatment in patients with limited-metastatic gastric or gastroesophageal adenocarcinoma (ROSETTE trial): an open-label, single-center, randomized phase 2 trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Ying Ying","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian Chen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen Bin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun Tang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue Hong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Hong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian Shu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao Qing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,1]]},"reference":[{"issue":"3","key":"14331_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"14331_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"FH Wang","year":"2024","unstructured":"Wang FH, Zhang XT, Tang L, Wu Q, Cai MY, Li YF, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 2024;44(1):127\u201372.","journal-title":"Cancer Commun"},{"issue":"4","key":"14331_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","volume":"21","author":"JA Ajani","year":"2023","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(4):393\u2013422.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"14331_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","unstructured":"Japanese Gastric Cancer Association. Japanese gastric Cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1\u201325.","journal-title":"Gastric Cancer"},{"key":"14331_CR5","doi-asserted-by":"crossref","unstructured":"Chen L, Chen Y. Survival benefits of gastrectomy in patients with metastatic gastric cancer: A meta-analysis. Adv Clin Exp Med. 2025;34(1):9\u201323.","DOI":"10.17219\/acem\/184268"},{"key":"14331_CR6","doi-asserted-by":"crossref","unstructured":"Knipper K, Lemties J, Krey T, Lyu SI, Wirsik NM, Schiffmann LM et al. Surgical and multimodal treatment of metastatic oesophageal cancer: retrospective cohort study. BJS Open. 2024;8(3):zrae054.","DOI":"10.1093\/bjsopen\/zrae054"},{"key":"14331_CR7","doi-asserted-by":"publisher","first-page":"1343596","DOI":"10.3389\/fonc.2024.1343596","volume":"14","author":"MG Maratta","year":"2024","unstructured":"Maratta MG, Vitale A, Basso M, Vivolo R, Di Monte E, Biondi A, et al. Benefit of a multimodal approach combining chemotherapy and surgery in oligometastatic gastric cancer: experience from a tertiary referral center. Front Oncol. 2024;14:1343596.","journal-title":"Front Oncol"},{"key":"14331_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2023.02.015","volume":"185","author":"TE Kroese","year":"2023","unstructured":"Kroese TE, van Laarhoven HWM, Schoppman SF, Deseyne P, van Cutsem E, Haustermans K, et al. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. Eur J Cancer. 2023;185:28\u201339.","journal-title":"Eur J Cancer"},{"key":"14331_CR9","doi-asserted-by":"publisher","first-page":"114062","DOI":"10.1016\/j.ejca.2024.114062","volume":"204","author":"TE Kroese","year":"2024","unstructured":"Kroese TE, Bronzwaer S, van Rossum PSN, Schoppman SF, Deseyne P, van Cutsem E, et al. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer. 2024;204:114062.","journal-title":"Eur J Cancer"},{"key":"14331_CR10","doi-asserted-by":"crossref","unstructured":"Zhan PL, Canavan ME, Ermer T, Pichert MD, Li AX, Maduka RC et al. Association between metastatic pattern and prognosis in stage IV gastric cancer: potential for stage classification reform. Ann Surg Oncol. 2023;30(7):4180\u20134191.","DOI":"10.1245\/s10434-023-13287-9"},{"issue":"3","key":"14331_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","volume":"17","author":"K Fujitani","year":"2016","unstructured":"Fujitani K, Yang H-K, Mizusawa J, Kim Y-W, Terashima M, Han S-U, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309\u201318.","journal-title":"Lancet Oncol"},{"issue":"5","key":"14331_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(10)70070-X","volume":"11","author":"I Songun","year":"2010","unstructured":"Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439\u201349.","journal-title":"Lancet Oncol"},{"issue":"1","key":"14331_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"10184","key":"14331_CR14","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet"},{"issue":"26","key":"14331_CR15","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, et al. PRODIGY: A phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric Cancer. J Clin Oncol. 2021;39(26):2903\u201313.","journal-title":"J Clin Oncol"},{"issue":"8","key":"14331_CR16","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081\u201392.","journal-title":"Lancet Oncol"},{"issue":"1","key":"14331_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12885-023-10773-x","volume":"23","author":"Y Cui","year":"2023","unstructured":"Cui Y, Yu Y, Zheng S, Ying Je D, Ya, Wang Y, et al. Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? A multicenter, prospective cohort study (Neo-REGATTA). BMC Cancer. 2023;23(1):308.","journal-title":"BMC Cancer"},{"issue":"9","key":"14331_CR18","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 2017;3(9):1237\u201344.","journal-title":"JAMA Oncol"},{"key":"14331_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3918-9","volume":"17","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction\u2013a phase III trial of the German AIO\/CAO-V\/CAOGI. BMC Cancer. 2017;17:1\u20137.","journal-title":"BMC Cancer"},{"issue":"17suppl","key":"14331_CR20","doi-asserted-by":"publisher","first-page":"LBA4001","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4001","volume":"42","author":"SE Al-Batran","year":"2024","unstructured":"Al-Batran SE, Lorenzen S, Riera J, Caca K, Mueller C, Stange DE, et al. Effect of chemotherapy\/targeted therapy alone vs. chemotherapy\/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: the IKF-575\/RENAISSANCE phase III trial. J Clin Oncol. 2024;42(17suppl):LBA4001\u2013LBA.","journal-title":"J Clin Oncol"},{"key":"14331_CR21","unstructured":"AJCC Cancer Staging Manual. 8 ed: Springer Cham; 2016."},{"key":"14331_CR22","unstructured":"Japanese Classification of Gastric Carcinoma. 15 ed. Tokyo: Kanehara Shuppan; 2017."},{"issue":"2","key":"14331_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10120-020-01136-7","volume":"24","author":"Y Iwasaki","year":"2021","unstructured":"Iwasaki Y, Terashima M, Mizusawa J, Katayama H, Nakamura K, Katai H, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer. 2021;24(2):492\u2013502.","journal-title":"Gastric Cancer"},{"issue":"17","key":"14331_CR24","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, et al. First-Line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-Year Follow-Up of the phase III checkmate 649 trial. J Clin Oncol. 2024;42(17):2012\u201320.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14331-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14331-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14331-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T19:35:19Z","timestamp":1748806519000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14331-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14331"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14331-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol has been approved by the lead ethics committee of Zhongshan Hospital, Fudan University (B2024-157R) and registered on ClinicalTrials.gov (NCT06468280, registration date: 05\/28\/2024). Informed consent will be obtained from all patients or their legal representatives, using a consent form approved by the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Study results will be published while ensuring patient confidentiality in compliance with the Declaration of Helsinki, Good Clinical Practice guidelines, the Data Protection Act, and local legal and regulatory requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"981"}}